Grant: Operating Grant
University of British Columbia
$743,020.00
Investigation of broadly cross-protective antibodies against influenza hemagglutinin and the development of better influenza vaccines
EF 2011-12
Résumé
Each year seasonal influenza kills hundreds of thousands of humans because vaccines need to be constantly updated and do not work well in the young or aged. Moreover there is no approved effective therapy for serious infections with influenza. The next influenza pandemic, which might occur at any time could be much more lethal than that in 2009 and mortality of avian H5N1 influenza is more than 50%. Influenza is such a problem the human immune response is very specific to various mutants of influenza virus, which occur continually. Surprisingly we found that humans can make antibodies (proteins that circulate in the blood and neutralize the influenza virus) that can neutralize a broad range of different influenza viruses. The planned research will lead to a vaccine that broadly protects against all types of influenza, both seasonal and pandemic influenza.
Programme
Operating Grant
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
239774
Name
Schrader John W
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Immunology & Transplantation
Projecttitle
Investigation of broadly cross-protective antibodies against influenza hemagglutinin and the development of better influenza vaccines
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$743,020
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Monoclonal Antibodies; Pandemic Preparedness; Seasonal And Pandemic Influenza; Vaccine
Abstract
Each year seasonal influenza kills hundreds of thousands of humans because vaccines need to be constantly updated and do not work well in the young or aged. Moreover there is no approved effective therapy for serious infections with influenza. The next influenza pandemic, which might occur at any time could be much more lethal than that in 2009 and mortality of avian H5N1 influenza is more than 50%. Influenza is such a problem the human immune response is very specific to various mutants of influenza virus, which occur continually. Surprisingly we found that humans can make antibodies (proteins that circulate in the blood and neutralize the influenza virus) that can neutralize a broad range of different influenza viruses. The planned research will lead to a vaccine that broadly protects against all types of influenza, both seasonal and pandemic influenza.
Competitiondate
201109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Schrader, John W
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $743,020~ $0~
